BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Nomura upgrades Sun Pharma to neutral
Gleevec approval is in-line with expectation. Failure to scale speciality business presents a downside risk to long-term growth assumptions, hence valuation multiples. Regulatory update on Halol facility and realisation of Ranbaxy synergy are the key catalysts for the stock.